Could a 27-employee Boston drug developer be headed toward a merger valued at $10 billion?

Boston Business Journal BioFlash editor Don Seiffert joins necn to discuss his story, "Here’s why some investors think Ziopharm is poised for a $10B merger."

Click here to read the full report.